Spyre Therapeutics (NASDAQ: SYRE) will present interim Phase 1 data for its IL‑23 antibody SPY003 at the European Crohn’s and Colitis Organisation (ECCO) Congress in Paris on February 18, 2026. The presentation will cover safety, pharmacokinetics and early efficacy signals from the first‑in‑human study, highlighting the antibody’s engineered extended half‑life that could enable quarterly or twice‑annual subcutaneous dosing.
The data showcase the first human evidence for Spyre’s next‑generation antibody platform, a milestone that validates the company’s design strategy and positions SPY003 as a potential patient‑friendly alternative to existing IL‑23 inhibitors that require more frequent administration. The extended half‑life feature is a key differentiator in the inflammatory bowel disease (IBD) market, where dosing convenience is a significant unmet need.
The ECCO Congress is a leading international forum for IBD research, and the presentation will allow investigators and clinicians to review the poster and accompanying materials in detail. The event also sets the stage for Spyre’s upcoming Phase 2 readouts scheduled for later in 2026 and in 2027, providing a roadmap for the candidate’s clinical development.
No market reaction data or analyst commentary is available at this time, but the presentation is expected to influence the perception of Spyre’s pipeline and its competitive positioning within the IBD therapeutic space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.